Oncology News

Researchers found evidence suggesting that tumor sizes at the margins of hepatocellular carcinoma-related transplantation criteria may be subject to inaccurate reporting, according to results of a recently published study.

The use of capecitabine as adjuvant therapy significantly extended survival of patients with biliary tract cancer, according to results of the BILCAP clinical trial scheduled for presentation at the ASCO Annual Meeting.

Nivolumab appeared safe and effective in patients with advanced liver cancer who did not respond to sorafenib, according to results from the CheckMate 040 study presented at the International Liver Congress 2017.

The FDA expanded the approval of regorafenib to include the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib.

Tiziana announced approval in Israel of a phase 2 clinical trial to test the safety of milciclib, a novel inhibitor of cell cycle dependent kinases, in patients with refractory hepatocellular carcinoma, according to a press release.

AMSTERDAM — Selective internal radiation therapy failed to best Nexavar in overall survival but did yield improvements in other parameters, including quality of life, in patients with hepatocellular carcinoma, according to data presented at the International Liver Congress.

AMSTERDAM — Approximately one-third of children under 18 years in the United Kingdom with hepatitis C developed serious long-term liver disease, according to data presented at the International Liver Congress.

AMSTERDAM — Curing patients with cirrhosis of hepatitis C virus could alter the inflammatory milieu and have an impact on the way CD8+ T-cells surveil potential carcinoma, according to data presented at the International Liver Congress.

AMSTERDAM — When adjusted for age and severity of liver disease, occurrence and recurrence of hepatocellular carcinoma after curing hepatitis C virus showed no difference between treatment with interferon or direct-acting antivirals, according to an expert at the International Liver Congress.

As we continue to see the success of direct-acting antiviral therapy in treating hepatitis C virus, we must be aware of any potential complications from the underlying liver disease after successful treatment, especially hepatocellular carcinoma.